Vaccinex's EBIT per Share for the
three
months ended in Mar. 2024 was $-2.92.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-46.40.
During the past 3 years, the average EBIT per Share Growth Rate was 46.30% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 45.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Vaccinex's EBIT per Share or its related term are showing as below:
VCNX'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 0.5 Med: 42.7 Max: 46.8
Current: 46.3
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Vaccinex was 46.80% per year. The lowest was 0.50% per year. And the median was 42.70% per year.
VCNX's 3-Year EBIT Growth Rate is ranked better than 91.72% of 1305
companies
in the Biotechnology industry
Industry Median: 3.5
vs VCNX: 46.30
Vaccinex's EBIT for the
three
months ended in Mar. 2024 was $-3.87 Mil.
Vaccinex EBIT per Share Historical Data
The historical data trend for Vaccinex's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-46.40
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vaccinex (NAS:VCNX) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Vaccinex EBIT per Share Related Terms
Thank you for viewing the detailed overview of Vaccinex's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb. The firm generates revenue from collaborative research, license, development and commercialization agreements.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VCNX has been successfully added to your 